Zacks Research Has Negative Outlook for Novavax Q3 Earnings

Key Points

• Zacks Research cut Novavax’s Q3 2026 EPS estimate to a loss of $0.33 from projected earnings of $0.08 and maintained a “Hold” rating, reflecting weaker profitability expectations.
• Novavax’s latest quarter showed a $0.32-per-share loss, though it beat estimates, while revenue fell 76.2% year over year to $56.7 million.
• The stock opened at $9.05, and analysts’ overall consensus remained “Hold” with a $14 average price target; hedge funds and other institutions own 53.04% of shares.

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Investment analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Novavax in a research note issued on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($0.33) for the quarter, down from their previous estimate of $0.08. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Novavax's current full-year earnings is ($0.43) per share. Zacks Research also issued estimates for Novavax's Q4 2026 earnings at $0.49 EPS, FY2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.58) EPS, Q1 2028 earnings at ($0.11) EPS, Q2 2028 earnings at ($0.17) EPS and FY2028 earnings at $0.78 EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%.The firm had revenue of $56.70 million for the quarter, compared to analysts' expectations of $52.51 million. During the same period in the previous year, the firm earned $0.62 earnings per share. The business's revenue was down 76.2% compared to the same quarter last year.

Several other research analysts have also commented on NVAX. Weiss Ratings restated a "sell (d)" rating on shares of Novavax in a report on Tuesday, August 4th. Wall Street Zen cut shares of Novavax from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. BTIG Research reissued a "buy" rating and issued a $19.00 price target on shares of Novavax in a research note on Thursday, June 11th. Finally, TD Cowen raised their price objective on shares of Novavax from $8.00 to $9.00 and gave the stock a "hold" rating in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Novavax has an average rating of "Hold" and a consensus price target of $14.00.

Novavax Stock Down 1.7%

NASDAQ:NVAX opened at $9.05 on Friday. The stock has a market cap of $1.49 billion, a P/E ratio of -5.95 and a beta of 2.46. The firm's fifty day simple moving average is $8.47 and its 200 day simple moving average is $8.93. Novavax has a twelve month low of $6.20 and a twelve month high of $11.97.

Institutional Trading of Novavax

Hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Novavax in the 3rd quarter worth about $33,000. Duncker Streett & Co. Inc. boosted its stake in Novavax by 917.3% during the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 3,825 shares in the last quarter. KBC Group NV boosted its stake in Novavax by 34.9% during the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 1,229 shares in the last quarter. Danske Bank A S purchased a new stake in Novavax in the third quarter worth about $64,000. Finally, State of Wyoming purchased a new stake in Novavax in the second quarter worth about $52,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: The FDA approved Novavax-Sanofi’s updated COVID-19 vaccine for the 2026–27 season, targeting the dominant XFG variant. The approval preserves Novavax’s participation in the U.S. COVID vaccine market, although eligibility is limited primarily to adults 65 and older and people with high-risk conditions. Reuters FDA vaccine approval article
• Neutral Sentiment: Novavax CEO John C. Jacobs was appointed to the board of Ambros Therapeutics, a move that highlights his industry experience but has no immediate financial impact on Novavax. Ambros Therapeutics board appointments article
• Negative Sentiment: Zacks Research made broad downward revisions to Novavax’s earnings outlook. Estimates were cut for Q3 2026 to a loss of $0.33 per share from expected earnings of $0.08, FY2026 to a loss of $0.23 from earnings of $0.03, FY2027 to a loss of $0.58 from earnings of $0.07, and FY2028 to earnings of $0.78 from $1.41. Estimates for Q1 2027, Q2 2028, and other future quarters were also reduced. While projections for Q4 2026 and Q2 2027 increased, the overall revisions indicate weaker profitability expectations. Zacks maintained a “Hold” rating. MarketBeat Novavax analyst estimates
• Negative Sentiment: Options activity showed unusually strong demand for downside protection, with traders purchasing 29,212 put options—172% above typical daily volume. The elevated put activity may signal increased hedging or bearish speculation. Novavax options activity article

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source